This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ewald, G. A. Articles by Eisenberg, P. R. Search for Related Content PubMed PubMed Citation Articles by Ewald, G. A. Articles by Eisenberg, P. R.

(Circulation. 1995;91:28-36.)
© 1995 American Heart Association, Inc.

Articles

Plasmin-Mediated Activation of Contact System in Response to Pharmacological Thrombolysis

Gregory A. Ewald, MD; Paul R. Eisenberg, MD, MPH

From the Cardiovascular Division, Washington University School of Medicine, St Louis, Mo.

Correspondence to Paul R. Eisenberg, MD, MPH, Washington University School of Medicine, Cardiovascular Division, Box 8086, 660 South Euclid Ave, St Louis, MO 63110.

Background Thrombin activity increases in patients treated with coronary thrombolysis for acute myocardial infarction, but the mechanisms are not well defined. We have shown that thrombin activity increases in plasma and whole blood incubated with plasminogen activators and appears to be plasmin mediated and dependent on activity of the factor VIIIa/IXa complex.

Methods and Results In the present study, increases in thrombin activity induced by incubation of recalcified citrated plasma with 0.16 to 0.5 µmol/L plasmin at 37°C were markedly attenuated in recalcified citrated plasma deficient in factors XI or XII, prekallikrein, or high molecular weight kininogen, as well as in plasma incubated with plasmin in the presence of 3.5 µmol/L corn trypsin inhibitor, a specific factor XIIa inhibitor. Increases in thrombin activity also occurred in nonanticoagulated whole blood incubated with pharmacological concentrations of plasminogen activators and were markedly attenuated in the presence of corn trypsin inhibitor. Plasmin-mediated (0.25 µmol/L) activation of purified factor XII occurred in 0.05 mol/L Tris-HCl and 0.012 mol/L NaCl (pH 7.8) at 37°C, resulting in equimolar quantities of two fragments that corresponded to cleavage of factor XII at Arg₃₅₃-Val₃₅₄, the site involved in kallikrein-mediated activation of factor XII, and cleavage at Lys₃₄₆-Ser₃₄₇, an apparently novel site of plasmin-mediated hydrolysis of factor XII. Contact activation was also demonstrated in plasma samples from patients after treatment with fibrinolytic agents for myocardial infarction, by demonstrating cleavage of high molecular weight kininogen from its one-chain to its two-chain form by ligand blotting with ¹²⁵I-prekallikrein.

Conclusions Plasmin-mediated activation of the contact system of coagulation appears to account, at least in part, for increases in procoagulant activity in patients treated with fibrinolytic agents. It may also explain hypotension, by release of bradykinin from high molecular weight kininogen, and complement activation, by activated factor XII, that has been demonstrated in these patients.

Key Words: factor XII • kininogens • fibrinolysis • myocardial infarction • pharmacology

This article has been cited by other articles:

				Q. Lian, S. J. Szarka, K. K. S. Ng, and S.-L. Wong Engineering of a Staphylokinase-based Fibrinolytic Agent with Antithrombotic Activity and Targeting Capability toward Thrombin-rich Fibrin and Plasma Clots J. Biol. Chem., July 11, 2003; 278(29): 26677 - 26686. [Abstract] [Full Text] [PDF]

				U. C. Nzeako, E. Frigas, and W. J. Tremaine Hereditary Angioedema: A Broad Review for Clinicians Arch Intern Med, November 12, 2001; 161(20): 2417 - 2429. [Abstract] [Full Text] [PDF]

				J.-C. ZHANG, K. CLAFFEY, R. SAKTHIVEL, Z. DARZYNKIEWICZ, D. E. SHAW, J. LEAL, Y.-C. WANG, F.-M. LU, and K. R. MCCRAE Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5 FASEB J, December 1, 2000; 14(15): 2589 - 2600. [Abstract] [Full Text]

				J. A. Samis, G. D. Ramsey, J. B. Walker, M. E. Nesheim, and A. R. Giles Proteolytic processing of human coagulation factor IX by plasmin Blood, February 1, 2000; 95(3): 943 - 951. [Abstract] [Full Text] [PDF]

				S. M. Bates and J. I. Weitz Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin Cardiovasc Res, February 1, 1999; 41(2): 418 - 432. [Abstract] [Full Text] [PDF]

				H. M. Hoffmeister, S. Szabo, C. Kastner, M. E. Beyer, U. Helber, S. Kazmaier, H. P. Wendel, W. Heller, and L. Seipel Thrombolytic Therapy in Acute Myocardial Infarction : Comparison of Procoagulant Effects of Streptokinase and Alteplase Regimens With Focus on the Kallikrein System and Plasmin Circulation, December 8, 1998; 98(23): 2527 - 2533. [Abstract] [Full Text] [PDF]

				J. I. Weitz, B. Leslie, and M. Hudoba Thrombin Binds to Soluble Fibrin Degradation Products Where it Is Protected From Inhibition by Heparin-Antithrombin but Susceptible to Inactivation by Antithrombin-Independent Inhibitors Circulation, February 17, 1998; 97(6): 544 - 552. [Abstract] [Full Text] [PDF]

				A. R. Zeibdawi and E. L. G. Pryzdial Mechanism of Factor Va Inactivation by Plasmin. LOSS OF A2 AND A3 DOMAINS FROM A Ca2+-DEPENDENT COMPLEX OF FRAGMENTS BOUND TO PHOSPHOLIPID J. Biol. Chem., June 1, 2001; 276(23): 19929 - 19936. [Abstract] [Full Text] [PDF]